目的 探讨巨噬细胞移动抑制因子(macrophage migration inhibitory factor，MIF)在脓毒血症所致急性肾损伤(acute kidney injury，AKI)早期诊断和预后评估中的意义。方法 回顾性选取2017年7月─2023年5月海安市人民医院收治的脓毒血症患者为研究对象。通过酶联免疫吸附试验检测患者入住重症监护病房时的血清MIF水平。收集患者的临床、实验室检查和28天死亡资料。比较AKI组和无AKI组的指标，并通过ROC曲线明确MIF鉴别脓毒血症患者是否合并AKI以及28天内是否死亡的能力。 结果 纳入的121例患者中有73例(60.33%)合并AKI。AKI组患者MIF水平高于非AKI组(t=7.883,P＜0.001)，28天内死亡组患者MIF水平高于存活组(t=5.092,P＜0.001)。多因素二元Logistic回归结果显示MIF水平(OR=3.240,95% CI：1.114～11.549,P=0.023)是脓毒血症患者合并AKI的独立危险因素。MIF鉴别脓毒血症患者是否发生AKI以及28天内死亡的曲线下面积分别为0.85和0.80。 结论 MIF水平升高是脓毒血症患者合并AKI和短期预后不良的危险因素，值得临床关注。

Objective  To explore the significance of macrophage migration inhibitory factor (MIF) in the early diagnosis and prognostic assessment of acute kidney injury (AKI) due to sepsis. Methods  A total of 121 patients with sepsis admitted to our hospital from July 2017 to May 2023 were retrospectively selected. The serum MIF levels at the time of admission to the intensive care unit were detected by enzyme-linked immunosorbent assay. Patient’s clinical and laboratory measurements and 28day mortality data were collected. Parameters in both the AKI and non-AKI groups were compared, and the ability of MIF to identify septic patients with or without comorbid AKI and with or without death within 28 days was clarified by the receiver-operating characteristics (ROC) curve. Results  Seventy-three (60.33%) of the included patients had combined AKI. MIF levels were significantly higher in patients in the AKI group than that in the non-AKI group [(6.82±1.58)ng/ml vs. (4.83±1.19)ng/ml, t=7.883, P＜0.001], and in the 28-day mortality group than those who survived 28 days [(7.33±1.74)ng/ml vs. (5.62±1.52)ng/ml, t=5.092, P＜0.001]. The results of multivariate binary logistic regression showed that MIF level (OR=3.240, 95% CI:1.114～11.549, P=0.023) was an independent risk factor for comorbid AKI in patients with sepsis. The area under the curve for MIF to identify AKI occurrence and 28day mortality in patients with sepsis were 0.85 and 0.80, respectively.  Conclusion    Elevated MIF level is a risk factor for comorbid AKI and poor short-term prognosis in patients with sepsis, which warrants clinical attention.